Logo Mark

Publication

Improvement of Patient-Reported Fatigue in IMerge Phase 3 Trial of Imetelstat vs. Placebo in Heavily Transfused Non-del (5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents

Download Now